pomalidomide has been researched along with palbociclib in 2 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (palbociclib) | Trials (palbociclib) | Recent Studies (post-2010) (palbociclib) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 911 | 126 | 864 |
| Protein | Taxonomy | pomalidomide (IC50) | palbociclib (IC50) |
|---|---|---|---|
| Chain B, Cell division protein kinase 6 | Homo sapiens (human) | 0.015 | |
| Chain B, Cell division protein kinase 6 | Homo sapiens (human) | 0.015 | |
| Cyclin-T1 | Homo sapiens (human) | 1.5085 | |
| Cyclin-K | Homo sapiens (human) | 1.207 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 9.8 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0109 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 9.8 | |
| Cyclin-A2 | Homo sapiens (human) | 2.2042 | |
| Acetylcholinesterase | Mus musculus (house mouse) | 0.021 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.0115 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 9.15 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 4.1887 | |
| G1/S-specific cyclin-D2 | Homo sapiens (human) | 0.0127 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.0194 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 3.48 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 1.1821 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 0.0631 | |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.018 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bendjennat, M; King, HM; Kizhake, S; Kour, S; Natarajan, A; Rana, S; Zahid, M | 1 |
| An, Z; Chandarlapaty, S; Deng, H; Gao, H; Li, Q; Rao, Y; Su, S; Wang, J; Wu, W; Yang, H; Yang, Z; Zhu, S | 1 |
2 other study(ies) available for pomalidomide and palbociclib
| Article | Year |
|---|---|
Selective degradation of CDK6 by a palbociclib based PROTAC.
Topics: Cyclin-Dependent Kinase 6; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Proteolysis; Pyridines; Structure-Activity Relationship | 2019 |
Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.
Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 6; Hematologic Neoplasms; HL-60 Cells; Humans; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Proteolysis; Pyridines; Small Molecule Libraries; Thalidomide; THP-1 Cells; Ubiquitin-Protein Ligases | 2019 |